Publications

Last 7 years

  1. Altered Signaling Pathways in Prostate Cancer Drive Metabolic Fate. Antico VG, Gueron G, Cotignola J, Vázquez E. International Journal of Scientific Research. September, 2017. In press.
  2. Heme oxygenase 1 governs the cytoskeleton at filopodia: pulling the brakes on the migratory capacity of prostate tumoral cells. Paez A, Vazquez E, Gueron G. Cell Death Discov. 2017 Apr 3;3:17020.
  3. In vivo hemin conditioning targets the vascular and immunological compartments and restrains prostate tumor development. Jaworski FM, Gentilini L, Gueron G, Meiss RP, Ortiz EG, Berguer PM, Ahmed A, Navone NM, Rabinovich GA, Compagno D, Laderach DJ, Vazquez ES. Clin Cancer Res. 2017 May 16. pii: clincanres.0112.2017. doi: 10.1158/1078-0432.CCR-17-0112. [Epub ahead of print]
  4. Heme oxygenase-1 in the forefront of a multi-molecular network that governs cell–cell contacts and filopodia-induced zippering in prostate cancer. Alejandra V Paez, Carla Pallavicini, Federico Schuster, Maria Pia Valacco, Jimena Giudice, Emiliano G Ortiz, Nicolás Anselmino, Estefania Labanca, Maria Binaghi, Marcelo Salierno, Marcelo A Martí, Javier H Cotignola, Anna Woloszynska-Read, Luciana Bruno, Valeria Levi, Nora Navone, Elba S Vazquez, and Geraldine Gueron. Cell Death Dis. 2016 Dec; 7(12): e2570. Published online 2016 Dec 29. doi: 10.1038/cddis.2016.420
  5. Improving risk stratification of patients with childhood acute lymphoblastic leukemia: Glutathione-S-Transferases polymorphisms are associated with increased risk of relapse. Leonardi DB, Abbate M, Riccheri MC, Nuñez M, Alfonso G, Gueron G, De Siervi A, Vazquez E, Cotignola J. Oncotarget. 2017 Jan 3; 8(1):110-117. doi: 10.18632/oncotarget.8606
  6. Heme-Oxygenase – 1 Implications in cell morphology and theadhesive behavior of prostate cancer cells. Gueron G, Giudice J, Valacco P, Paez A, Eguero B, Toscani AM; Jaworski F; Coluccio Leskow F; Cotignola J; Marti M; Binaghi M; Navone N; Vazquez E. Oncotarget 2014 Jun; 5(12): 4087–4102. Published online 2014 Mar 16. doi: 10.18632/oncotarget.1826
  7. Differential effect of heterocyclid D-Ribofuranoside derivatives on human prostate cancer cell viability and cell cycle progression. Gueron G, Avanzo R, Schuster F, Carabelos N, Vazquez E, Fascio M; D’Accorso N. Biomedicine and Pharmacotherapy. 2014 Sep;68(7):847-54. doi: 10.1016/j.biopha.2014.08.010. Epub 2014 Aug 19
  8. Prostate tumor growth is impaired by CtBP1 depletion inhigh fat diet fed mice. Moiola CP, De Luca P, Zalazar F, Cotignola J, Rodriguez-Segui S, Gardner K, Meiss R, Vallecorsa P, Pignataro O, Mazza O, Vazquez E, De Siervi A. Clin Cancer Res. 2014 Aug 1;20(15):4086-95. doi: 10.1158/1078-0432.CCR-14- 0322. Epub 2014 May 19.
  9. Prostate Cancer Cell–Stroma Cell Cross-Talk via FGFR1 Mediates Antitumor Activity of Dovitinib in Bone Metastases. Wan X, Corn P, Yang J, Palanisamy N, Starbuck M, Efstathiou E, Tapia E, Zurita A, Aparicio A, Ravoori M, Vazquez E, Robinson D, Wu Y, Cao X, Iyer M, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan A, Logothetis C, Navone. N.Sci. Transl. Med. 6 (2014) 252ra1222 In Press. DOI: 10.1126/scitranslmed.3009332
  10. Heme Oxygenase-1 (HO-1) Expression in Prostate Cancer Cells Modulates the Oxidative Response in Bone Cells. Ferrando M, Wan X, Meiss R, Yang J, De Siervi A, Navone N, Vazquez E. PLoS One. 2013 Nov 4;8(11):e80315. doi: 10.1371/journal.pone.0080315.
  11. BRCA1 and p53 regulate critical prostate cancer pathways. De Luca P, Moiola C, Zalazar F, Gardner K, Vazquez E, De Siervi A. Prostate Cancer Prostatic Dis. 16 (2013) 233–238.
  12. Glutathione-S-Transferase (GST) polymorphisms are associated with relapse after radical prostatectomy. Cotignola J, Leonardi D, Shahabi A, Acuña A, Stern M, Navone N, Scorticati C, De Siervi A, Mazza O, Vazquez E. Prostate Cancer Prostatic Dis. 16 (2013) 28-34. doi: 10.1038/pcan.2012.45. Epub 2012 Nov 13. Glutathione-S-Transferase (GST) polymorphisms are associated with relapse after radical prostatectomy.
  13. Identification of a unique galectin signature during human prostate cancer progression places galectin-1 as a major therapeutic target in advanced stages of the disease. Laderach D, Gentilini L, Giribaldi L, Cardenas Delgado V, Nugnes L, Croci D, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp M, Vazquez E, Chauchereau A, Kutok J, Rodig S, Elola M, Compagno D, Rabinovich G. Cancer Res. 73 (2013) 86-96. doi: 10.1158/0008-5472.CAN-12-1260. Epub 2012 Oct 29.
  14. Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation. Elguero B, Gueron G, Giudice J, Toscani M, De Luca P, Zalazar F, Coluccio Leskow F, Meiss R, Navone N, De Siervi A, Vazquez E. Neoplasia 14 (2012) 1043-56.
  15. Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription. Moiola C, De Luca P, Cotignola J, Gardner K, Vazquez E, De Siervi A. Cell. Physiol. Biochem. 30 (2012) 596-608.
  16. Activation of Beta-Catenin Signaling in Androgen Receptor-Negative Prostate Cancer Cells. Wan X, Liu J, Lu J, Tzelepi V, Yang J, Starbuck M, Diao L, Wang J, Efstathiou E, Vazquez E, Troncoso P, Maity S, Navone N. Clin. Cancer Res. 18 (2012) 726-36.
  17. Effect of transforming growth factor beta (TGF-b) receptor I kinase inhibitor on prostate cancer bone growth. Wan X, Li Z, Starbuck, Yang J, Starbuck M, Ravoori M, Kundra V, Vazquez E, Navone N. Bone 50 (2012) 695-703.
  18. Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behaviour. Gueron G, De Siervi A, Vazquez E. (Review) Prostate Cancer Prostatic Dis. 15 (2012) 213-21 doi: 10.1038/pcan.2011.64.
  19. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Ferrando* M, Gueron* G, Elguero B, Giudice J, Salles A, Coluccio Leskow F, Jares-Erijman E, Colombo L, Meiss R, Navone N, De Siervi A, Vazquez E. (*co-first authors) Angiogenesis 14 (2011) 467-79. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer.
  20. Key questions in metastasis: new insights in molecular pathways and therapeutic implications. Gueron G, De Siervi A, Vazquez E. (Review) Current Pharmaceutical Biotechnology 12 (2011) 1867- 80.
  21. BRCA1 loss induces GADD153-mediated Doxorubicin resistance in Prostate Cancer. De Luca P, Vazquez E, Moiola C, Zalazar F, Cotignola J, Gueron G, Gardner K, De Siervi A. Mol. Cancer Res. 9 (2011) 1078-90.

Comments are closed